A Chinese delegation led by Vice Premier Liu He could be sent before month's end to iron out phase one, a source tells CNBC's Kayla Tausche.Marketsread more
"But I expect we'll have a deal," Mnuchin tells CNBC.Politicsread more
Wall Street analysts were largely skeptical of Trump's announcement on Friday of a substantial trade deal.Marketsread more
Apple will release the iPhone SE2 early next year for $399, analyst Ming-Chi Kuo says.Tech Driversread more
Sanders, who is recovering from a heart attack, reveals the new tax plan a day before the third Democratic debate.2020 Electionsread more
The Treasury secretary expresses optimism that the U.S. and China have a workable first-phase agreement.Economyread more
The ITB, the homebuilder's ETF, has its highest level since January 2018. Craig Johnson, chief market technician at Piper Jaffray, thinks there could be even more room to run.Trading Nationread more
However, that doesn't mean it won't cause harm, says Gottlieb. "You can't inhale something into the lungs on a repeated basis and not cause some damage to the lung."Health and Scienceread more
Climate change activists targeted BlackRock, the world's biggest asset manager, in London on Monday, demanding that the world's major financial institutions stop funding what...Environmentread more
The Salesforce CEO called for the establishment of a "new capitalism" that's partly funded by taxing the rich.Technologyread more
Industrials are gearing up for big gains, says Piper Jaffray's Craig Johnson. Here's one way to play the breakout.Trading Nationread more
Incyte stands to benefit from unveiling data on its cancer treatments at a key conference in the coming days, a biotechnology analyst said Friday.
Many big-name biotech and pharmaceutical companies will present drug developments at the American Society of Clinical Oncology annual meeting, which runs until Tuesday. Many treatments will focus on immuno-oncology, which directs the natural immune system to fight cancer cells.
"A lot of innovation" has taken place in that category of cancer therapy, said Eric Schmidt, a biotech analyst at Cowen and Co. He noted that Incyte may play a huge role in the treatment.
"Of all the stocks we're following, Incyte's probably gonna be my top nominee to make it there with the PD-1s," he said in a CNBC "Power Lunch" interview.
Incyte shares have jumped more than 50 percent higher this year.
He also outlined his expectations for Puma Biotechnology's "highly touted" breast cancer treatment. Puma shares plummeted this month when the company unveiled slightly disappointing Phase 3 results for its experimental drug.
Puma will present full data at the conference. Schmidt noted that the drug was "successful" based on early trials and "ought to be approved on that basis."